Cardiac Monitoring Devices Market Intelligence: Size, Share and Growth Outlook Through 2035

Market Overview

Size, clinical burden, and observation-time economics

• Brevintel analysis values the market at USD 15 billion in 2025 ($15B), rising from USD 16 billion in 2026 to USD 29 billion by 2035 ($29B) at a 6.8% CAGR.
• Medtronic led with over 25% share in 2025; Abbott Laboratories, Medtronic, Philips, Boston Scientific Corporation, and BIOTRONIK collectively held 52%.
• Cardiovascular diseases caused an estimated 19.8 million deaths in 2022, or about 32% of global deaths, while heart attack and stroke accounted for 85% of those deaths.
• Global cardiovascular disease prevalence reached 626 million cases in 2023, compared with 311 million in 1990, according to a 2025 Journal of the American College of Cardiology assessment covering 204 countries and territories from 1990 to 2023.
• Atrial fibrillation affected 52.55 million people in 2021, up from 22.21 million in 1990, and remains a principal indication for prolonged rhythm surveillance.
• The number of people aged 60 years or older is expected to reach 1.4 billion by 2030, from 1 billion in 2020.
• Brevintel analysis indicates that 6.8% growth through 2035 is being shaped less by replacement demand for conventional ECG equipment than by the economic value of extending observation time.
• The 52.55 million global atrial fibrillation prevalence base in 2021 provides a clinical foundation for longer monitoring in atrial fibrillation and syncope workups, where intermittent events can escape short tests.

Installed base versus longer-duration demand

• As the pool of patients with hypertension, diabetes, ischemic disease, and age-related conduction disorders expands, the clinical limitation of a single resting ECG becomes more consequential.
• Monitoring duration, signal quality, and the ability to route clinically meaningful events into physician workflows are becoming more important purchase criteria.
• Long-duration patches, mobile telemetry, and insertable monitors generate more data than episodic testing, making alert precision and remote workflow integration central to adoption.
• Suppliers that lower false-alert burden while preserving clinically relevant episodes can make longer monitoring periods viable for cardiology practices and health systems.

Market Dynamics

Clinical and demographic drivers

• The population aged 65 years and older is projected to rise from 770.4 million in 2022 to 1.58 billion by 2050, supporting demand across standard ECG, Holter, telemetry, patch, and insertable-monitor pathways.
• Atrial fibrillation prevalence among people aged 65 years and older reached about 38.96 million in 2021, and diagnostic need often extends from an outpatient ECG to an ambulatory patch, telemetry service, or insertable monitor.
• Modifiable risk factors accounted for an estimated 79.6% of the global cardiovascular disease burden in 2023, widening the target population beyond the oldest age groups.
• Hypertension, obesity, diabetes, tobacco exposure, and inactivity expand demand in diagnostic centers and outpatient practices, while also heightening the need for lower-cost devices where remote-monitoring reimbursement is limited.
• Acute and high-risk patients support demand for telemetry and continuous monitoring, whereas primary-care and prevention pathways favor accessible ECG systems and wearable screening tools.
• The appropriate modality depends on symptom frequency, clinical acuity, and the availability of downstream interpretation rather than a single interchangeable device class.

Technology, interoperability, and AI

• iRhythm launched its Zio ECG Recording and Analysis System in Japan in May 2025, offering an AI-powered long-term continuous monitoring service with up to 14 days of recording.
• A 2025 study of AI-assisted direct-to-physician ambulatory ECG reporting reported 98.6% sensitivity for critical arrhythmias, compared with 80.3% for trained ECG technicians in the evaluated workflow.
• AliveCor received FDA clearance in June 2024 for its Kardia 12L ECG System and KAI 12L AI technology, which together support 35 cardiac determinations.
• The American Heart Association has identified data interoperability, security, and governance as material issues for ambulatory cardiovascular monitoring.
• Connected-monitoring suppliers consequently compete on integration with clinical systems and the quality of their data-management architecture, rather than on electrode and recorder design alone.
• Handheld and consumer-facing ECG systems can bring diagnostic-quality acquisition closer to primary, urgent, and distributed-care settings without eliminating physician interpretation.

Privacy, cost, and access constraints

• Remote cardiac monitoring handles sensitive rhythm, symptom, and physiological data across patient devices, connectivity layers, cloud platforms, and clinical workstations.
• The GDPR imposes requirements concerning lawful processing, purpose limitation, data minimization, and safeguards for health data, affecting product design and the pace of connected-monitoring deployment in European markets.
• The FTC's amended Health Breach Notification Rule took effect on July 29, 2024, broadening notification obligations for certain health applications and connected devices that are not covered by HIPAA.
• Insertable cardiac monitors, mobile cardiac telemetry, and AI-enabled extended-wear patches can require implantation, connectivity, clinical review, service infrastructure, and ongoing data-management capacity.
• Where reimbursement is fragmented, procurement tends to remain concentrated in tertiary facilities or shift toward conventional ECG and Holter equipment.
• Brevintel analysis indicates that clinical demand alone will not determine category growth; the strongest opportunities arise where longer monitoring duration is paired with an economically workable review model.

Segmentation Analysis

Device type

• ECG monitors hold 34.5% of the 2025 market because resting and continuous ECG remain foundational tools for initial rhythm and ischemia assessment.
• Holter monitors account for 16.5% of the 2025 market and retain a role where multi-channel recordings, established clinical pathways, and cost discipline matter.
• Event recorders and external loop recorders represent 6.7% of the market and rank fifth by CAGR among device types because patient-triggered design is disadvantaged when symptoms are absent.
• Mobile cardiac telemetry devices account for 15.6% of the 2025 market and rank second by CAGR, with value in continuous transmission and time-sensitive escalation.
• Implantable cardiac monitors account for 15.2% of the market and are the fastest-growing device type for unexplained syncope, cryptogenic stroke evaluation, and covert atrial fibrillation detection.
• Medtronic reported that its AccuRhythm AI update for Reveal LINQ targeted an 85% cumulative reduction in false atrial fibrillation and pause alerts while preserving high true-alert sensitivity.
• BIOTRONIK reported that BIOMONITOR IV's SmartECG algorithm reduced false detections while retaining clinically relevant episodes, addressing an adoption bottleneck for long-term monitoring teams.
• Other device types, including patch-based monitors and related wearable systems, hold 11.5% share as an intermediate position between brief Holter studies and real-time telemetry.

Type

• Non-wearable devices account for 52% of the 2025 market through hospital ECG workstations, bedside telemetry, stationary diagnostic systems, and implantable monitors.
• Wearable devices account for 48% and are the fastest-growing type segment, projected to reach USD 14.2 billion by 2035.
• Growth is tied to convenience, longer recording windows, and a care model that captures rhythm data during ordinary activity.
• The segment's expansion does not imply a uniform shift to consumer devices; physician-prescribed patches and clinically integrated wearables remain important where diagnostic reports must feed formal treatment decisions.

Application

• Arrhythmia detection holds 56.58% of the 2025 market, reflecting both disease prevalence and the mismatch between intermittent expression and brief clinical tests.
• Atrial fibrillation represents 65.1% of this application, followed by tachycardia at 18.8%, bradycardia at 9.2%, and PACs/PVCs at 6.9%.
• Cardiac ischemia and myocardial infarction detection account for 19.0% of the market, placing more weight on signal fidelity and timely clinical response than on patient wear time.
• Heart rate and rhythm monitoring accounts for 8.0% and is the fastest-growing application, supported by connected wearables and remote follow-up.
• Syncope and palpitation monitoring represents 9.67% of the market and ranks second by CAGR because causative rhythm disturbances may be infrequent.
• Pre/post-operative monitoring accounts for 4.33%, supported by surveillance around cardiac procedures and high-acuity episodes.
• Other applications account for 2.42%.

End use

• Hospitals hold 42.9% of the market, or USD 6.4 billion in 2025, remaining the central setting for acute diagnosis, intensive monitoring, perioperative care, and device implantation.
• Their fourth-place CAGR reflects a mature installed base rather than reduced clinical importance.
• Diagnostic centers account for 24.6% and provide a lower-cost outpatient venue for Holter analysis, ambulatory ECG studies, and related cardiac assessments.
• Ambulatory surgery centers hold 17.1% and rank second by CAGR as selected cardiac procedures migrate toward lower-cost procedural settings.
• Homecare settings account for 11.3% and are the fastest-growing end-use segment, reflecting remote monitoring workflows and patient-worn devices.
• Other end users account for 4.1%.
• Brevintel analysis estimates the mix is moving toward observation models that fit intermittent disease, with insertable monitors and mobile telemetry gaining where the cost of a missed episode exceeds the cost of extended monitoring.

Regional Outlook

North America and Europe

• North America holds the largest market share in 2025, reflecting specialist infrastructure, broad use of ambulatory monitoring, and a reimbursement environment capable of supporting advanced diagnostic pathways.
• The U.S. market reached USD 5.6 billion in 2025, from USD 5.2 billion in 2024.
• Heart disease remains a leading U.S. cause of death, and approximately 805,000 people experience a heart attack each year.
• Canada contributes through hospital-based ECG, Holter, and ambulatory monitoring adoption.
• Europe accounts for USD 4.2 billion in 2025, with Germany, the UK, France, Spain, Italy, and the Netherlands supporting demand through established cardiology services and hospital networks.
• Philips reported a UK pilot at University Hospitals Sussex using ePatch monitoring and Cardiologs AI analysis for two-week ambulatory ECG studies.
• The EU regulatory and privacy environment raises the importance of compliance-ready connected platforms, tying implementation to local procurement and data-governance requirements.

Asia Pacific, Latin America, and Middle East & Africa

• Asia Pacific is the fastest-growing region, at an approximately 7.5% CAGR, combining large patient populations in China, Japan, India, Australia, and South Korea with uneven access to advanced cardiac diagnostics.
• Japan offers a particularly favorable setting for long-duration monitoring because of population aging and mature clinical infrastructure, illustrated by iRhythm's May 2025 launch of the Zio service.
• China and India create a different configuration: urban tertiary centers can adopt advanced systems, while broad-based expansion depends on affordable ECG, Holter, and wearable offerings.
• Australia and South Korea support uptake of digitally connected monitoring through comparatively mature healthcare and technology ecosystems.
• Brazil, Mexico, and Argentina represent a developing Latin American opportunity shaped by cardiovascular disease burden and aging, but constrained by reimbursement fragmentation, import dependence, and public-procurement budgets.
• South Africa, Saudi Arabia, and the UAE anchor Middle East and Africa demand, with Saudi Arabia and the UAE offering stronger near-term potential for advanced monitoring.
• Brevintel analysis suggests North America and parts of Europe can reward workflow efficiency and interoperability, while Asia Pacific's approximately 7.5% CAGR reflects a larger but bifurcated expansion runway.

Competitive Landscape

Structure and recent developments

• Competition spans diversified medtech companies with hospital-monitoring infrastructure and specialized providers focused on ambulatory, insertable, or personal ECG modalities.
• Medtronic's AccuRhythm AI update was applied to Reveal LINQ devices in the U.S., Australia, and New Zealand in 2024, with a projected 85% cumulative reduction in false atrial fibrillation and pause alerts, marking 10 Years of the Reveal LINQ ICM.
• Philips in 2025 introduced an ECG AI Marketplace, with Anumana's ECG-AI Low Ejection Fraction algorithm as the initial offering, and announced an integration collaboration with Epic's Aura specialty diagnostics suite.
• Boston Scientific's cardiac-monitoring portfolio includes the LUX-Dx insertable cardiac monitor family and the LATITUDE Clarity data-management platform.
• BIOTRONIK introduced BIOMONITOR IV at the 2024 EHRA Congress after CE Mark approval and partnered with the University of Sydney in 2025 to evaluate connected-health innovations through 2028.
• Abbott's Assert-IQ insertable cardiac monitor received CE Mark in March 2024; the Assert-IQ EL+ option is designed for more than six years of monitoring.
• GE HealthCare highlighted an integrated cardiology pathway and ComboLab AltiX AI.i at ESC 2025 through its MAC and MUSE cardiology-information-system offerings.
• iRhythm received FDA 510(k) clearance in October 2024 for Zio AT design updates and launched the Zio ECG Recording and Analysis System in Japan in May 2025 through distributor Senko Medical Instrument.
• AliveCor received FDA clearance in June 2024 for Kardia 12L and KAI 12L AI, then introduced KardiaMobile 6L Max and KardiaAlert in May 2025.
• MicroPort presented cardiac rhythm management and electrophysiology solutions through MicroPort CRM at EHRA 2025.
• BPL Medical introduced ExcelSign modular patient monitors and the Relife 1000 biphasic defibrillator at ISACON in December 2025.
• Schiller AG's medilog portfolio supports extended ambulatory ECG recording and analysis for clinics that need richer recordings than a basic short-term Holter study.

Integrated producers

• Medtronic
• Philips
• Abbott Laboratories
• Boston Scientific Corporation
• GE HealthCare

Specialty suppliers

• BIOTRONIK
• iRhythm Technologies
• AliveCor
• MicroPort
• BPL Medical
• Schiller AG